OcuCure Therapeutics Inc.

Tubulin is attracting increasing attention as a potential target to halt angiogenesis in the eye as well as in tumors. OcuCure Therapeutics Inc. is one of several firms developing it to treat macular degeneration. If this approach proves to be as effective as anti-VEGF approaches like Lucentis, OcuCure could be positioned to win over a significant share of the market as its drug would be administered topically, not via injection in the eye.